Skip to main content

Free Content Long‐term clinical and immunologic outcomes of HIV‐infected women with and without previous exposure to nevirapine

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Abstract
Objectives

To determine and compare the clinical and immunologic outcomes for HIV‐infected women initiated on antiretroviral therapy (ART), with and without previous exposure to single‐dose nevirapine in the MTCT‐Plus programme – Kampala, Uganda, from 2003 to 2011.
Methods

Retrospective comparison of prospectively collected programmatic data of clinical and immunologic treatment outcomes among HIV‐infected Ugandan women, with and without prior exposure to sdNVP, who received NNRTI‐based ART for a median follow‐up of 6 years.
Results

Of the 408 women in the programme, 289 (70.8%) were started on ART, of whom 205 (70.9%) had prior exposure to sdNVP. Clinical, immunologic and combined (clinical and or immunologic) treatment failure occurred in 29 (10.0%), 132 (45.7%) and 142 (49.1%) women, respectively. There was no significant difference in the distribution of time to immunologic failure for women by exposure to sdNVP (log‐rank P = 0.98). In Cox proportional hazard modelling, exposure to sdNVP was not associated with immunologic failure [adjusted hazard ratio (HR) = 0.89, 95% confidence interval (CI): 0.61–1.30]. CD4 count >100 cells/mm3 at initiation was associated with reduced incidence of immunologic failure in adjusted analyses (HR = 0.32, 95% CI: 0.22–0.48).
Conclusions

HIV‐infected Ugandan women initiated on an NVP‐based ART regimen had similar immunologic treatment outcomes irrespective of previous NVP exposure. CD4 cell count prior to initiating HAART was a key prognostic factor for successful long‐term immunologic treatment outcomes. In poor settings, regular follow‐up of patients on HAART with adequate counselling to promote adherence and safe disclosure may promote low clinical failure rates.

Language: French

Document Type: Research Article

DOI: https://doi.org/10.1111/tmi.12054

Publication date: 2013-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more